Henan Lingrui Pharmaceutical Co Ltd (600285) — Capital Reinvestment Ratio
Henan Lingrui Pharmaceutical Co Ltd (600285) has a Capital Reinvestment Ratio of 0.04x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥140.12 Million) in capital expenditures (CN¥5.61 Million). Check 600285 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Henan Lingrui Pharmaceutical Co Ltd Capital Reinvestment Ratio (1999–2025)
This chart tracks Henan Lingrui Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 26 annual periods. For the full cash flow conversion analysis, see 600285 operating cash flow.
Annual Capital Reinvestment Ratio for Henan Lingrui Pharmaceutical Co Ltd (1999–2025)
Year-by-year Capital Reinvestment Ratio for Henan Lingrui Pharmaceutical Co Ltd from 1999 to 2025. See cash generation quality of Henan Lingrui Pharmaceutical Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.10x | CN¥553.88 Million | CN¥56.83 Million | ▼ -21.9% |
| 2024 | 0.13x | CN¥875.86 Million | CN¥115.11 Million | ▲ +404.3% |
| 2023 | 0.03x | CN¥813.43 Million | CN¥21.20 Million | ▼ -19.4% |
| 2022 | 0.03x | CN¥834.91 Million | CN¥26.99 Million | ▼ -64.4% |
| 2021 | 0.09x | CN¥845.69 Million | CN¥76.91 Million | ▼ -43.0% |
| 2020 | 0.16x | CN¥450.53 Million | CN¥71.82 Million | ▲ +21.5% |
| 2019 | 0.13x | CN¥450.15 Million | CN¥59.04 Million | ▲ +9.7% |
| 2018 | 0.12x | CN¥436.25 Million | CN¥52.14 Million | ▼ -95.1% |
| 2017 | 2.43x | CN¥105.97 Million | CN¥257.55 Million | ▼ -29.5% |
| 2016 | 3.45x | CN¥63.26 Million | CN¥218.05 Million | ▲ +541.7% |
| 2015 | 0.54x | CN¥156.82 Million | CN¥84.23 Million | ▼ -34.6% |
| 2014 | 0.82x | CN¥124.32 Million | CN¥102.10 Million | ▼ -37.4% |
| 2013 | 1.31x | CN¥127.27 Million | CN¥166.88 Million | ▼ -79.9% |
| 2012 | 6.51x | CN¥15.43 Million | CN¥100.53 Million | ▲ +312.7% |
| 2011 | 1.58x | CN¥40.49 Million | CN¥63.90 Million | ▲ +364.2% |
| 2009 | 0.34x | CN¥132.61 Million | CN¥45.08 Million | ▼ -55.8% |
| 2008 | 0.77x | CN¥43.72 Million | CN¥33.63 Million | ▼ -72.6% |
| 2007 | 2.81x | CN¥15.99 Million | CN¥44.84 Million | ▲ +353.4% |
| 2006 | 0.62x | CN¥26.76 Million | CN¥16.56 Million | ▲ +8.0% |
| 2005 | 0.57x | CN¥33.43 Million | CN¥19.15 Million | ▼ -50.0% |
| 2004 | 1.14x | CN¥35.51 Million | CN¥40.65 Million | ▼ -33.3% |
| 2003 | 1.72x | CN¥23.79 Million | CN¥40.81 Million | ▲ +120.3% |
| 2002 | 0.78x | CN¥69.41 Million | CN¥54.06 Million | ▼ -92.9% |
| 2001 | 10.93x | CN¥3.41 Million | CN¥37.29 Million | ▲ +6.1% |
| 2000 | 10.31x | CN¥3.66 Million | CN¥37.76 Million | ▲ +778.6% |
| 1999 | 1.17x | CN¥4.81 Million | CN¥5.64 Million | — |